Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, unique proteins that regulate vital biological functions that are impaired in various disease states. Targacept’s clinical pipeline includes multiple Phase 2 product candidates, all representing first-in-class opportunities. Targacept leverages its scientific leadership and diverse pipeline to attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com.
Company Details
- Employees
- 31
- Founded
- 1997
- Address
- 100 North Main Street,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- targacept.com
- HQ
- Winston-Salem, NC
Targacept, Inc. Questions
Targacept, Inc.'s website is targacept.com
Targacept, Inc.'s LinkedIn profile is https://www.linkedin.com/company/targacept-inc.
Targacept, Inc. has
31 employees.
View email and phone details for 31
employees at Targacept, Inc..
Targacept, Inc.'s industry is
Biotechnology Research
Targacept, Inc.'s top competitors are
Heckel America,
Xoder Technologies,
Eisai Us,
Prokidney Corp.,
Grifols,
Takeda,
Abbvie,
Novartis,
Amgen,
Mercodia.
Targacept, Inc.'s categories are Biotechnology Research
Targacept, Inc.'s founding year is 1997
